APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Soft Capsules Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Soft Capsules Drugs Market Outlook and Growth Opportunities 2026

Report ID 17403664042 January 2026203 pages

Choose your research edition.

Industry ResearchSoft Capsules Drugs Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Soft Capsules Drugs Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Soft Capsules Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Soft Capsules Drugs Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Soft Capsules Drugs Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Soft Capsules Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Soft Capsules Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Soft Capsules Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Soft Capsules Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Soft Capsules Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Soft Capsules Drugs market include GSK, A&Z Pharmaceutical, Atrium Innovations, Blackmores, Boehringer Ingelheim, By-health, Chiesi, Nature Made and Sumitomo Dainippon, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Soft Capsules Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Soft Capsules Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Soft Capsules Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Soft Capsules Drugs market.

Soft Capsules Drugs Segment by Company

GSK

A&Z Pharmaceutical

Atrium Innovations

Blackmores

Boehringer Ingelheim

By-health

Chiesi

Nature Made

Sumitomo Dainippon

The Clorox Company

Vertex

AstraZeneca

Roche

Merck

Novartis

Teva

Abbott

Soft Capsules Drugs Segment by Type

Liquid Core Drugs

Semi-solid Core Drugs

Soft Capsules Drugs Segment by Application

Hospital Pharmacy

Retail Pharmacy

Soft Capsules Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Soft Capsules Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Soft Capsules Drugs key companies, revenue, market share, and recent developments.

3. To split the Soft Capsules Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Soft Capsules Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Soft Capsules Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Soft Capsules Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Soft Capsules Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Soft Capsules Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Soft Capsules Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Soft Capsules Drugs industry.

Chapter 3: Detailed analysis of Soft Capsules Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Soft Capsules Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Soft Capsules Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Soft Capsules Drugs Industry Trends Table 2. Soft Capsules Drugs Industry Drivers Table 3. Soft Capsules Drugs Industry Opportunities and Challenges Table 4. Soft Capsules Drugs Industry Restraints Table 5. Global Soft Capsules Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Soft Capsules Drugs Revenue Share by Company (2021-2026) Table 7. Global Soft Capsules Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Soft Capsules Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Soft Capsules Drugs Company, Product Type & Application Table 10. Global Soft Capsules Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Soft Capsules Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Liquid Core Drugs Table 15. Significant Companies of Semi-solid Core Drugs Table 16. Global Soft Capsules Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Soft Capsules Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Soft Capsules Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Soft Capsules Drugs Sales Value Share by Type (2021-2026) Table 20. Global Soft Capsules Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Pharmacy Table 22. Significant Companies of Retail Pharmacy Table 23. Global Soft Capsules Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Soft Capsules Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Soft Capsules Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Soft Capsules Drugs Sales Value Share by Application (2021-2026) Table 27. Global Soft Capsules Drugs Sales Value Share by Application (2027-2032) Table 28. Global Soft Capsules Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Soft Capsules Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Soft Capsules Drugs Sales Value Share by Region (2021-2026) Table 31. Global Soft Capsules Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Soft Capsules Drugs Sales Value Share by Region (2027-2032) Table 33. Global Soft Capsules Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Soft Capsules Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Soft Capsules Drugs Sales Value Market Share by Country (2021-2026) Table 36. Global Soft Capsules Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Soft Capsules Drugs Sales Value Market Share by Country (2027-2032) Table 38. GSK Company Information Table 39. GSK Business Overview Table 40. GSK Soft Capsules Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. GSK Soft Capsules Drugs Product Portfolio Table 42. GSK Recent Development Table 43. A&Z Pharmaceutical Company Information Table 44. A&Z Pharmaceutical Business Overview Table 45. A&Z Pharmaceutical Soft Capsules Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. A&Z Pharmaceutical Soft Capsules Drugs Product Portfolio Table 47. A&Z Pharmaceutical Recent Development Table 48. Atrium Innovations Company Information Table 49. Atrium Innovations Business Overview Table 50. Atrium Innovations Soft Capsules Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Atrium Innovations Soft Capsules Drugs Product Portfolio Table 52. Atrium Innovations Recent Development Table 53. Blackmores Company Information Table 54. Blackmores Business Overview Table 55. Blackmores Soft Capsules Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Blackmores Soft Capsules Drugs Product Portfolio Table 57. Blackmores Recent Development Table 58. Boehringer Ingelheim Company Information Table 59. Boehringer Ingelheim Business Overview Table 60. Boehringer Ingelheim Soft Capsules Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Boehringer Ingelheim Soft Capsules Drugs Product Portfolio Table 62. Boehringer Ingelheim Recent Development Table 63. By-health Company Information Table 64. By-health Business Overview Table 65. By-health Soft Capsules Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. By-health Soft Capsules Drugs Product Portfolio Table 67. By-health Recent Development Table 68. Chiesi Company Information Table 69. Chiesi Business Overview Table 70. Chiesi Soft Capsules Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Chiesi Soft Capsules Drugs Product Portfolio Table 72. Chiesi Recent Development Table 73. Nature Made Company Information Table 74. Nature Made Business Overview Table 75. Nature Made Soft Capsules Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Nature Made Soft Capsules Drugs Product Portfolio Table 77. Nature Made Recent Development Table 78. Sumitomo Dainippon Company Information Table 79. Sumitomo Dainippon Business Overview Table 80. Sumitomo Dainippon Soft Capsules Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Sumitomo Dainippon Soft Capsules Drugs Product Portfolio Table 82. Sumitomo Dainippon Recent Development Table 83. The Clorox Company Company Information Table 84. The Clorox Company Business Overview Table 85. The Clorox Company Soft Capsules Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. The Clorox Company Soft Capsules Drugs Product Portfolio Table 87. The Clorox Company Recent Development Table 88. Vertex Company Information Table 89. Vertex Business Overview Table 90. Vertex Soft Capsules Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Vertex Soft Capsules Drugs Product Portfolio Table 92. Vertex Recent Development Table 93. AstraZeneca Company Information Table 94. AstraZeneca Business Overview Table 95. AstraZeneca Soft Capsules Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. AstraZeneca Soft Capsules Drugs Product Portfolio Table 97. AstraZeneca Recent Development Table 98. Roche Company Information Table 99. Roche Business Overview Table 100. Roche Soft Capsules Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Roche Soft Capsules Drugs Product Portfolio Table 102. Roche Recent Development Table 103. Merck Company Information Table 104. Merck Business Overview Table 105. Merck Soft Capsules Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Merck Soft Capsules Drugs Product Portfolio Table 107. Merck Recent Development Table 108. Novartis Company Information Table 109. Novartis Business Overview Table 110. Novartis Soft Capsules Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Novartis Soft Capsules Drugs Product Portfolio Table 112. Novartis Recent Development Table 113. Teva Company Information Table 114. Teva Business Overview Table 115. Teva Soft Capsules Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Teva Soft Capsules Drugs Product Portfolio Table 117. Teva Recent Development Table 118. Abbott Company Information Table 119. Abbott Business Overview Table 120. Abbott Soft Capsules Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Abbott Soft Capsules Drugs Product Portfolio Table 122. Abbott Recent Development Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Soft Capsules Drugs Product Image Figure 2. Global Soft Capsules Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Soft Capsules Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Soft Capsules Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Liquid Core Drugs Image Figure 8. Semi-solid Core Drugs Image Figure 9. Global Soft Capsules Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Soft Capsules Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Soft Capsules Drugs Sales Value Share by Type (2021-2032) Figure 12. Hospital Pharmacy Image Figure 13. Retail Pharmacy Image Figure 14. Global Soft Capsules Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Soft Capsules Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Soft Capsules Drugs Sales Value Share by Application (2021-2032) Figure 17. Global Soft Capsules Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Soft Capsules Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Soft Capsules Drugs Sales Value (2021-2032) & (US$ Million) Figure 20. North America Soft Capsules Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Soft Capsules Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Soft Capsules Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Soft Capsules Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Soft Capsules Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Soft Capsules Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. South America Soft Capsules Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Soft Capsules Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Soft Capsules Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Soft Capsules Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Liquid Core Drugs
  • Semi-solid Core Drugs
Applications
  • Hospital Pharmacy
  • Retail Pharmacy
Companies covered
  • GSK
  • A&Z Pharmaceutical
  • Atrium Innovations
  • Blackmores
  • Boehringer Ingelheim
  • By-health
  • Chiesi
  • Nature Made
  • Sumitomo Dainippon
  • The Clorox Company
  • Vertex
  • AstraZeneca
  • Roche
  • Merck
  • Novartis
  • Teva
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Soft Capsules Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Soft Capsules Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Soft Capsules Drugs Market Dynamics
  1. 2.1 Soft Capsules Drugs Industry Trends
  2. 2.2 Soft Capsules Drugs Industry Drivers
  3. 2.3 Soft Capsules Drugs Industry Opportunities and Challenges
  4. 2.4 Soft Capsules Drugs Industry Restraints
3 Soft Capsules Drugs Market by Company
  1. 3.1 Global Soft Capsules Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Soft Capsules Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Soft Capsules Drugs Company Ranking (2024-2026)
  4. 3.4 Global Soft Capsules Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Soft Capsules Drugs Company Product Type and Application
  6. 3.6 Global Soft Capsules Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Soft Capsules Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Soft Capsules Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Soft Capsules Drugs Market by Type
  1. 4.1 Soft Capsules Drugs Type Introduction
  2. 4.1.1 Liquid Core Drugs
  3. 4.1.2 Semi-solid Core Drugs
  4. 4.2 Global Soft Capsules Drugs Sales Value by Type
  5. 4.2.1 Global Soft Capsules Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Soft Capsules Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Soft Capsules Drugs Sales Value Share by Type (2021-2032)
5 Soft Capsules Drugs Market by Application
  1. 5.1 Soft Capsules Drugs Application Introduction
  2. 5.1.1 Hospital Pharmacy
  3. 5.1.2 Retail Pharmacy
  4. 5.2 Global Soft Capsules Drugs Sales Value by Application
  5. 5.2.1 Global Soft Capsules Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Soft Capsules Drugs Sales Value by Application (2021-2032)
  7. 5.2.3 Global Soft Capsules Drugs Sales Value Share by Application (2021-2032)
6 Soft Capsules Drugs Regional Value Analysis
  1. 6.1 Global Soft Capsules Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Soft Capsules Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Soft Capsules Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Soft Capsules Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Soft Capsules Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Soft Capsules Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Soft Capsules Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Soft Capsules Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Soft Capsules Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Soft Capsules Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Soft Capsules Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Soft Capsules Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Soft Capsules Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Soft Capsules Drugs Sales Value Share by Country, 2025 VS 2032
7 Soft Capsules Drugs Country-level Value Analysis
  1. 7.1 Global Soft Capsules Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Soft Capsules Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Soft Capsules Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Soft Capsules Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Soft Capsules Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Soft Capsules Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Soft Capsules Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Soft Capsules Drugs Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 A&Z Pharmaceutical
  8. 8.2.1 A&Z Pharmaceutical Company Information
  9. 8.2.2 A&Z Pharmaceutical Business Overview
  10. 8.2.3 A&Z Pharmaceutical Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 A&Z Pharmaceutical Soft Capsules Drugs Product Portfolio
  12. 8.2.5 A&Z Pharmaceutical Recent Developments
  13. 8.3 Atrium Innovations
  14. 8.3.1 Atrium Innovations Company Information
  15. 8.3.2 Atrium Innovations Business Overview
  16. 8.3.3 Atrium Innovations Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Atrium Innovations Soft Capsules Drugs Product Portfolio
  18. 8.3.5 Atrium Innovations Recent Developments
  19. 8.4 Blackmores
  20. 8.4.1 Blackmores Company Information
  21. 8.4.2 Blackmores Business Overview
  22. 8.4.3 Blackmores Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Blackmores Soft Capsules Drugs Product Portfolio
  24. 8.4.5 Blackmores Recent Developments
  25. 8.5 Boehringer Ingelheim
  26. 8.5.1 Boehringer Ingelheim Company Information
  27. 8.5.2 Boehringer Ingelheim Business Overview
  28. 8.5.3 Boehringer Ingelheim Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Boehringer Ingelheim Soft Capsules Drugs Product Portfolio
  30. 8.5.5 Boehringer Ingelheim Recent Developments
  31. 8.6 By-health
  32. 8.6.1 By-health Company Information
  33. 8.6.2 By-health Business Overview
  34. 8.6.3 By-health Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 By-health Soft Capsules Drugs Product Portfolio
  36. 8.6.5 By-health Recent Developments
  37. 8.7 Chiesi
  38. 8.7.1 Chiesi Company Information
  39. 8.7.2 Chiesi Business Overview
  40. 8.7.3 Chiesi Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Chiesi Soft Capsules Drugs Product Portfolio
  42. 8.7.5 Chiesi Recent Developments
  43. 8.8 Nature Made
  44. 8.8.1 Nature Made Company Information
  45. 8.8.2 Nature Made Business Overview
  46. 8.8.3 Nature Made Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Nature Made Soft Capsules Drugs Product Portfolio
  48. 8.8.5 Nature Made Recent Developments
  49. 8.9 Sumitomo Dainippon
  50. 8.9.1 Sumitomo Dainippon Company Information
  51. 8.9.2 Sumitomo Dainippon Business Overview
  52. 8.9.3 Sumitomo Dainippon Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sumitomo Dainippon Soft Capsules Drugs Product Portfolio
  54. 8.9.5 Sumitomo Dainippon Recent Developments
  55. 8.10 The Clorox Company
  56. 8.10.1 The Clorox Company Company Information
  57. 8.10.2 The Clorox Company Business Overview
  58. 8.10.3 The Clorox Company Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 The Clorox Company Soft Capsules Drugs Product Portfolio
  60. 8.10.5 The Clorox Company Recent Developments
  61. 8.11 Vertex
  62. 8.11.1 Vertex Company Information
  63. 8.11.2 Vertex Business Overview
  64. 8.11.3 Vertex Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Vertex Soft Capsules Drugs Product Portfolio
  66. 8.11.5 Vertex Recent Developments
  67. 8.12 AstraZeneca
  68. 8.12.1 AstraZeneca Company Information
  69. 8.12.2 AstraZeneca Business Overview
  70. 8.12.3 AstraZeneca Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AstraZeneca Soft Capsules Drugs Product Portfolio
  72. 8.12.5 AstraZeneca Recent Developments
  73. 8.13 Roche
  74. 8.13.1 Roche Company Information
  75. 8.13.2 Roche Business Overview
  76. 8.13.3 Roche Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Roche Soft Capsules Drugs Product Portfolio
  78. 8.13.5 Roche Recent Developments
  79. 8.14 Merck
  80. 8.14.1 Merck Company Information
  81. 8.14.2 Merck Business Overview
  82. 8.14.3 Merck Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Merck Soft Capsules Drugs Product Portfolio
  84. 8.14.5 Merck Recent Developments
  85. 8.15 Novartis
  86. 8.15.1 Novartis Company Information
  87. 8.15.2 Novartis Business Overview
  88. 8.15.3 Novartis Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Novartis Soft Capsules Drugs Product Portfolio
  90. 8.15.5 Novartis Recent Developments
  91. 8.16 Teva
  92. 8.16.1 Teva Company Information
  93. 8.16.2 Teva Business Overview
  94. 8.16.3 Teva Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Teva Soft Capsules Drugs Product Portfolio
  96. 8.16.5 Teva Recent Developments
  97. 8.17 Abbott
  98. 8.17.1 Abbott Company Information
  99. 8.17.2 Abbott Business Overview
  100. 8.17.3 Abbott Soft Capsules Drugs Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Abbott Soft Capsules Drugs Product Portfolio
  102. 8.17.5 Abbott Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst